Welcome to our dedicated page for Cargo Therapeutics SEC filings (Ticker: CRGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CRGX SEC filings archive documents the regulatory history of CARGO Therapeutics, Inc., a former Nasdaq-listed, clinical-stage biotechnology company focused on developing next-generation cell therapies for cancer patients. These filings provide insight into CARGO’s clinical programs, platform technologies, financial position, governance, and the corporate actions that led to its acquisition and delisting.
For this company, Forms 10‑K, 10‑Q and 8‑K historically detailed progress in its CAR T‑cell pipeline, including firicabtagene autoleucel (firi‑cel), an autologous CD22 CAR T‑cell therapy candidate studied in large B‑cell lymphoma after CD19 CAR T‑cell therapy, and CRG‑023, a tri‑specific CAR T targeting CD19, CD20 and CD22. Filings also described CARGO’s novel allogeneic platform, characterized as a universal vector solution designed to limit immune‑based rejection and enable durable responses of CAR T‑cell therapy.
Later-period Form 8‑K reports are especially important for understanding CARGO’s strategic transition. They include disclosures about the discontinuation of the FIRCE‑1 Phase 2 study, the decision to cease development operations, workforce reductions, and the company’s exploration of strategic alternatives. Subsequent 8‑K filings outline the Agreement and Plan of Merger with Concentra Biosciences, LLC, the completion of the tender offer and merger, and the resulting change in control under which CARGO became a wholly owned subsidiary of Concentra.
Trading and registration changes are captured in Form 25, filed by The Nasdaq Stock Market LLC, which notifies the SEC of the removal of CARGO’s common stock from listing and registration under Section 12(b) of the Exchange Act, and in Form 15‑12G, filed by CARGO to terminate registration under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d). Together, these documents confirm that CRGX is a defunct public listing.
On Stock Titan, these historical filings are paired with AI‑powered summaries that explain the key points of each document in accessible language. Users can quickly understand major clinical disclosures, strategic decisions, and the mechanics of the merger and deregistration, while still having access to the full original SEC texts for deeper review.
CARGO Therapeutics, Inc. (CRGX) – Form 4 filing
The filing discloses that director Abraham Bassan received a stock-option grant for 25,000 shares of CRGX common stock on 18 June 2025. The option carries an exercise price of $4.35 and will expire on 17 June 2035.
Vesting is 100% on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholders’ meeting, contingent upon continued service. No shares were sold or otherwise disposed of; Bassan’s beneficial ownership now includes the 25,000 unexercised options, recorded as directly held.
The transaction appears to be a routine equity incentive designed to align director interests with those of shareholders. There are no accompanying cash transactions, sales, or changes in ownership structure noted in this filing.
CARGO Therapeutics, Inc. (CRGX) – Form 4 insider filing dated 06/20/2025
The filing discloses a single equity-based transaction involving Director Kapil Dhingra. On 06/18/2025, Dr. Dhingra was granted a stock option for 25,000 common shares with an exercise price of $4.35 per share. The option vests 100 % on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholder meeting, provided the director continues to serve the company. The option expires on 06/17/2035. After this grant, Dr. Dhingra now holds 25,000 derivative securities (options) directly.
No non-derivative share transactions were reported, and there were no sales or exercises associated with the option. The transaction was reported on a Form 4 filed by one reporting person; no 10b5-1 trading plan box was checked. The filing represents routine director compensation rather than an open-market purchase or sale.
For investors, the disclosure indicates additional potential dilution of up to 25,000 shares (≈0.1 % of a typical small-cap biotech float) should the option be exercised, while also aligning the director’s incentives with long-term shareholder value via equity compensation.
CARGO Therapeutics, Inc. (CRGX) – Form 4 filing dated 20 June 2025
The filing discloses that non-employee director David Charles Lubner received a routine equity incentive on 18 June 2025: a stock option for 25,000 shares of common stock with an exercise price of $4.35 and an expiration date of 17 June 2035. All 25,000 options will vest 100 % on the earlier of (i) the one-year anniversary of the grant date or (ii) the company’s next annual meeting, conditional upon the director’s continued service. Following this grant, Mr. Lubner beneficially owns 25,000 derivative securities, held directly. No open-market purchases, sales, or changes to non-derivative share ownership were reported.
Because the filing represents a standard board option grant, it does not alter the company’s capital structure or signal insider buying or selling of common shares. The information is therefore operationally routine and financially immaterial for most investors, though it demonstrates continued alignment of director incentives with shareholder value.
CARGO Therapeutics, Inc. (CRGX) filed a Form 4 disclosing a routine equity award to director Jane Henderson.
On 18 June 2025, Henderson received a stock option covering 25,000 common shares with an exercise price of $4.35. The option vests 100 % on the earlier of (i) 18 June 2026 or (ii) the company’s next Annual Meeting, contingent on her continued board service. The instrument carries a 10-year term, expiring 17 June 2035. Following the grant, Henderson’s beneficial ownership of derivative securities totals 25,000 options; no non-derivative share transactions were reported.
The filing is noted as a single-person submission, confirms Henderson’s status solely as a director, and contains no indication of a Rule 10b5-1 trading plan. No sales, purchases, or other equity movements were disclosed beyond this compensatory award.